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This thesis presents studies with respect to the epidemiology of asthma in
chi ldren with and without nocturnal symptoms as wel l  as i ts underly ing
pathophysiology. Nocturnal respiratory symptoms are the cl in ical  expression
of nocturnal air f low l imitat ion and indicate a more severe disease state, also
named'nocturnal asthma'.  Much research has been performed in the past
decades on the underly ing mechanisms of nocturnal air f low l imitat ion. This
thesis set out to contr ibute to a better insight into i ts pathophysiology by
invest igat ing the role of serum cort isol  evels.
In chapter 2 we provide an overview of the prevalence of nocturnal
respiratory symptoms and the endogenous and exogenous factors that
contr ibute to the pathophysiology of nocturnal air f low l imitat ion in chi ldhood
asthma, as far as known at the start  of  this research. So far i t  was wel l
establ ished that endogenous factors may contr ibute to nocturnal air f low
l imitat ion i .e.  the autonomic nervous system t- '  ,  inf lammatory processes
measured as changes in airway responsiveness a and di f ferences in numbers
of eosinophi ls and neutrophi l  granulocytes at night obtained from peripheral
blood and/or bronchoalveolar lavage. s 'B One of the most important
exogenous factors in the Netherlands is exposure to high house dust mite
al lergen levels.  e Another important contr ibut ing exogenous factor is
environmental  tobacco smoke.
Chapter 3 discusses the treatment strategies for chi ldren with nocturnal
respiratory symptoms. Inhaled cort icosteroids are st i l l  the treatment of
choice when symptoms persist .  They have been shown to reduce day- and
nightt ime symptoms, reduce the degree of airway responsiveness and
decrease the number of asthma exacerbat ions. Long-act ing p2-agonists have,
by their  long last ing effects clear ly shown to reduce the number of night ly
awak ings .
In chapter 4 we describe the prevalence of awakening due to nocturnal
respiratory symptoms, i ts inf luence on dayt ime act iv i t ies, and exposure to
parental  c igarette smoking by a quest ionnaire in chi ldren with and without
asthma. 555 chi ldren with doctor diagnosed asthma (0-16 years) and 763
control  subjects (0-16 vears) part ic ipated. FEVl as o/o predicted was
measured in al l  chi ldren with asthma > 6 years, and in a random sample of
102 control  subjects.  Both groups suffered from awakening due to nocturnal
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respiratory symptoms, the prevalence being signi f icant ly higher in chi ldren
with asthma. Nocturnal cough was the most frequently reported symptom,
yet in the age group 0-4 years i t  was not signi f icant ly di f ferent between
control  subjects (360/0) and chi ldren with asthma (460/0).  The prevalence of
nocturnal respiratory symptoms dropped with increasing age in both groups.
Thir ty f ive per cent of the asthma group and 11.5olo f  the control  group
reported that nocturnal respiratory symptoms affected daytime activities. As
little as 34.3o/o of the asthma group reported their nocturnal symptoms
spontaneously.
This study is the f i rst  one to compare the prevalence of nocturnal respiratory
complaints in both healthy subjects and in chi ldren with asthma from 0-16
years. I t  shows that the prevalence of nocturnal cough is comparable in
asthmatics and healthy chi ldren of age 0-4 years. Furthermore, i t  stresses
once again the necessity that doctors ask specif ical ly for nocturnal respiratory
symptoms in chi ldren with asthma, since reduct ion of nocturnal symptoms
has been shown to improve dayt ime act iv i t ies.
New treatment strategies, such as early inst i tut ion of inhaled cort icosteroids
and long-act ing B2-agonists have been introduced in the ninet ies to improve
nocturnal asthma symptoms and lung funct ion. In chapter 5 we invest igated
a cohort  of  86 asthmatic chi ldren (0-16 years) of an outpat ient c l in ic
populat ion who answered a quest ionnaire in 1991 and 1998. We assessed
whether changes in therapeut ic approach over this period of seven years
resulted in a decreased prevalence of nocturnal respiratory symptoms due to
air f low l imitat ion. FEVl o/o predicted was measured in al l  asthmatic chi ldren 6
years and older (n=42).  Furthermore we assessed predict ing factors for
nocturnal respiratory symptoms and changes in FEVI o/o predicted between
1991 and 1998.
The prevalence of awakening due to nocturnal respiratory symptoms
significantly decreased over a period of seven years from 62 o/o to 33 o/o.
Inhaled corticosteroid (ICS) use increased significantly from 59 o/o in 1991 to
79 o/o in 1998. In the group of chi ldren who used ICS on a dai ly basis during
the whole seven years period, FEV1 % predicted values were significantly
higher in 1998 compared to 1991. Addit ional use of long-act ing p2-agonists in
1998 did not have a complementary effect on the FEV1 o/o predicted values in
1998. These results support  the idea that the use of long term ICS in chi ldren
with nocturnal respiratory symptoms might have a benef ic ial  inf luence on the
development of their  respiratory health.
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We hypothesised that decreased serum cortisol levels may contribute to
nocturnal airway obstruct ion in chi ldren with asthma. This might ei ther be
due to lower cort isol  evels at night or to an overal l  24-h lower serum cort isol
level in chi ldren with nocturnal air f low l imitat ion. In chapter 6 we
invest igated i f endogenous cort isol  evels are lower, and also whether the 24-
h var iat ion of cort isol  is greater,  in chi ldren with asthma than in control
subjects and assessed the relationship between serum cortisol and nocturnal
air f low l imitat ion in chi ldren with asthma. Cort isol  and FEVl were measured
every 4 h over a period of 24 h; blood eosinophi ls,  airway responsiveness to
methachol ine and adenosine-5'-mono-phosphate (AMP) at 0400 and 1600 h
Chi ldren with asthma had lower cort isol  evels than control  subjects;  only at
midnight the di f ference was signi f icant.  Subjects with nocturnal asthma (24-h
FEVI variation > 15olo) had significantly lower cortisol levels than control
subjects at 0000, 0800 and 1200 h. A higher mean 24-h cort isol  level in
subjects with asthma was associated with a signi f icant ly higher FEVI as a
percentage of the predicted value (FEV1 o/o pred) at 0400, 0800 and 2000 h,
yet not in control subjects. Higher 24-h cortisol variation was associated with
lower FEVI o/o pred at all time points in both control subjects and at almost all
t ime points in subjects with non-nocturnal asthma. There was no signi f icant
association between the level or variation of cortisol and the level of PDzo
methachol ine (provocat ive dose of methachol ine causing a 2oo/o fal l  in FEVr)
and PD2s AMP, or the number of blood eosinophi ls,  Our data suggest that
lower cortisol levels contribute to overall lower levels of FEVI in asthmatic
chi ldren, and especial ly at  night.  This may be due to a lack of suppression of
airway inf lammation.
In view of the above demonstrated relationship between FEVI o/o pred values
and serum cort isol  levels we invest igated whether subst i tut ion of low serum
cortisol with intravenous hydrocortisone would improve FEVI variation and
whether i t  would improve indirect measures of airway inf lammation. This is
out l ined in chapter 7. Intravenous hydrocort isone was given during 24 h in a
double bl ind randomised crossover design to 26 chi ldren with asthma. FEVI
was measured every 4 h during 24 h, blood eosinophi l  numbers and airway
responsiveness to methachol ine and adenosine 5'-monophosphate (AMP) at
0400 and 1600 h. Infusion of hydrocort isone signi f icant ly increased cort isol
levels in al l  pat ients during the night and morning hours. FEVI values were
higher at al l  t ime points in chi ldren with nocturnal asthma which was
signif icant at 0800 h during infusion of hydrocort isone. This was not observed
in the non-nocturnal asthma group. The median (range) numbers of blood
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eosinophi ls at 0400 h decreased signi f icant ly in the whole asthma group,
f rom 0 .61  (0 .05-1 .42)  to  0 .52  (0 .05-1 .79)  10e/ l  .  PD26 methacho l ine  d id  no t
signi f icant ly change, whereas PD20 AMP improved only signi f icant ly at 1600 h
in the NA-group, from 72,0 (0.13-144.0) mglml to 144.0 (2.25-144.O)
mglml.  The current study shows that subst i tut ion of lower endogenous 24-h
values of cort isol  improves lung funct ion in asthmatic chi ldren. Together with
the previous observat ion that asthmatic chi ldren have lower FEVI values and
cort isol  evels than healthy chi ldren, this signi f ies the importance of cort isol  in
the pathophysiology of asthma. Furthermore a short period of hydrocortisone
infusion reduces the number of circulating eosinophils, to be considered as a
marker of inf lammation, whereas i t  does not change the severi ty of airway
hyperresponsiveness to methachol ine. The improvement of AMP
responsiveness was signi f icant at 1600 h in only the non-nocturnal asthma
group/ whereas the number of eosinophi ls decreased only signi f icant ly at
0400 h. Thus, improvement in AMP responsiveness could not simply be
explained by reduced airway inf lammation. The underly ing mechanism of the
improvement in FEVI values is not ful ly c lear.  I t  is possible that the
supranormal blood levels of cortisol reached by hydrocortisone treatment
mainly causes decreased edema of the airway wal l ,  thereby improving FEVI
especial ly in the chi ldren with more severe airway wal l  edema, i .e.  the
nocturnal asthma group. Thus edema reduct ion may play a large role, next to
a theoret ical ly plausible ant i- inf lammatory effect.
Eosinophi ls and lymphocytes are bel ieved to be key effector cel ls of airway
wal l  inf lammation in asthma, releasing pro- inf lammatory mediators and
cytokines. Next to eosinophi ls and lymphocytes, neutrophi ls may play an
addit ional role,  especial ly dur ing exacerbat ions of asthma and viral
respiratory infections. It may be proposed that activation of monocytes
and/or epithel ial  cel ls can funct ion as a source of the chemokine IL-8.
Corticosteroids are known for their potent anti-inflammatory activity in
al lergic asthma. Decrease of serum cort isol  levels at night may be of great
importance in the loss of control of the inflammatory response. In chapter 8
we present he results of an addit ional study that might contr ibute to explain
the observed improvement in FEVI by cort isol  as descr ibed in chapter 7. This
study invest igated 16 chi ldren with moderately severe asthma. I t  was
designed to invest igate whether a day and night di f ference xists in IL-4, IL-
5, IL-8 and IFN-y product ion of concanaval ine A st imulated peripheral  blood
mononuclear cells (PBMC's), important cytokines in the inflammatory process
of allergic asthma. Furthermore, we performed this study to identify whether
1 1 3
Chapter 9
substitution of low serum cortisol levels with intravenous hydrocortisone
would decrease those cytokines, in order to explain the observed increase in
FEVI during subst i tut ion of intravenous hydrocort isone. Median (range)
values of IFN-y, IL-4, IL-5 and IL-8 produced by PBMC's did not s igni f icant ly
di f fer,  nei ther between day- and nightt ime values, nor between the
measurements with sal ine at 0400 and 1600 h and with hydrocort isone, The
earl ier f indings of improvement in nocturnal and morning FEVI values after
subst i tut ion of low endogenous cort isol  levels with a low dose intravenous
hydrocort isone could not be explained by a decreased release of the above
mentioned cytokines in peripheral  blood PBMC's. We hypothesise that
glucocort icosteroids play an indirect role in eosinophi l ic and neutrophi l ic
airway inf lammation. This may wel l  run via a strong inhibi t ion of epi thel ial
t issue cel l .  Thus the posit ive effect of  glucocort icosteroids on FEVI values
may be explained by the effect on the activation state of local tissue cells
thereby suppressing airway inf lammation and vascular leakage.
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